About Achaogen
Achaogen is a publicly listed company based in United States founded in 2004. Antibiotics for multi-drug resistant bacterial infections are developed. Achaogen has raised $100.91 million across 8 funding rounds from investors including Gates Foundation, Arch Venture Partners and Frazier Healthcare Partners. The company has 42 employees. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Bacterial. Its competitors include Spero Therapeutics, Melinta Therapeutics and Adaptive Phage Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Achaogen was founded in 2004 in the United States within the biotechnology sector. Antibiotics are developed by the company to address multi-drug resistant bacterial infections. Plazomicin is advanced as the lead candidate for treating serious infections caused by MDR Enterobacteriaceae, including carbapenem-resistant strains. Further efforts include a program for small molecule LpxC inhibitors targeting Pseudomonas aeruginosa and Acinetobacter baumannii, alongside a therapeutic antibody initiative for gram-negative bacteria.
- Headquarters United States
- Employees 42
- Stage Public
- SectorsHealthcare
- Website achaogen.com
- Social LinkedIn X
- Annual Revenue$3.3 M (USD)-70as on Dec 31, 2018
- Net Profit-$186.51 M (USD)-48as on Dec 31, 2018
- EBITDA-$189.17 M (USD)-50as on Dec 31, 2018
- Total Equity Funding$100.91M (USD)
in 8 rounds
- Latest Funding Round$10M (USD), Post-IPO
May 2017
- InvestorsGates Foundation
& 9 more
- Employee Count42
Funding Insights of Achaogen
Achaogen has successfully raised a total of $100.91M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $10 million completed in May 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $100.91M
- Total Rounds 8
- Last Round Post-IPO — $10M
- First Round $26M
(Oct 2006)
- Investors Count 10
All 8 funding rounds of Achaogen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2017 | $10M | Post-IPO | – | – | |
| May 2017 | $10.5M | Grant | – | – | |
| Jun 2016 | $25.45M | Post-IPO | – | – | – |
| Mar 2013 | $18.91M | Series C | – | – | – |
| May 2012 | $2.5M | Grant | – | – | |
| Apr 2010 | $56M | Series C | – | Frazier Healthcare Partners, Alta Partners | |
| Dec 2008 | $2.72M | Grant | – | – | |
| Oct 2006 | $26M | Series B | – | – |
10 investors in total: 10 institutional.
Investors in Achaogen
Achaogen has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Gates Foundation, Arch Venture Partners and Frazier Healthcare Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare sector private equity investments are managed by the firm. | 1991 | frazierhealthcare.com | Seattle, United States | |
Venture capital firm focused on healthcare companies | altapartners.com | Jackson, United States | ||
Venture capital fund backed incubator focused on the healthcare startups | 5amventures.com | San Francisco, United States | ||
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Life science & tech focused VC firm investing in the US | domainvc.com | Princeton, United States | ||
Venture capital firm focused on tech sectors | venrock.com | Palo Alto, United States | ||
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | versantventures.com | |||
Charitable foundation investments on poverty reduction and healthcare | 2000 | gatesfoundation.org | Seattle, United States | |
Wellcome is a global charitable foundation focused on health research. | wellcome.ac.uk | London, United Kingdom | ||
Administers health care and support for military personnel and operations. | health.mil | Falls Church, United States |
Investor details for Achaogen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Achaogen
2 people are tracked at Achaogen (2 in team); the tracked headcount is 42.
| Name | Role | Group |
|---|---|---|
Noe Reyes | Veterinarian/Scientist | Team |
shuang wu | scientist | Team |
Complete people profiles for Achaogen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Achaogen
4 dated milestones of Achaogen across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Achaogen is founded.
- Funding First funding round of $26.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $10.0M.
Competitors of Achaogen
Achaogen has 3 listed competitors in our database, 3 of them funded. They include Spero Therapeutics, Melinta Therapeutics and Adaptive Phage Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sperotherapeutics.com | 2013 | Cambridge, United States | $114.7M | 46 | Therapeutics for drug-resistant bacterial infections are developed. | |
| melinta.com | 2000 | Morristown, United States | $186M | 290 | Developer of bacterial ribosome-targeting drugs for MDR infections | |
| aphage.com | 2016 | Bethesda, United States | $107.87M | 78 | Therapies for multi-drug resistant infections are developed using bacteriophages. |
Detailed competitors of Achaogen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Achaogen
Websites that share an audience with Achaogen (achaogen.com).
Websites whose visitors overlap most with Achaogen. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
biotechduediligence.com | biotechduediligence.com | 100% | – | ||
ir.momentapharma.com | ir.momentapharma.com | 91% | – | ||
| ardelyx.com | 90% | 17.8K | #2,305,983 | View details |
Top companies in Infectious Diseases
3 companies that operate in the same segment as Achaogen (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Achaogen
Complete news archive for Achaogen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Achaogen
Achaogen was founded in 2004 and raised its 1st funding round 2 years after it was founded.
Achaogen is headquartered in United States.
Achaogen is a funded company, having raised a total of $100.91M across 8 funding rounds to date. The company's 1st funding round was a Series B of $26M, raised on Oct 2006.
Achaogen has 42 employees.
Annual revenue of Achaogen is $3.3M as on Dec 31, 2018.
Achaogen was founded in 2004 in the United States within the biotechnology sector. Antibiotics are developed by the company to address multi-drug resistant bacterial infections. Plazomicin is advanced as the lead candidate for treating serious infections caused by MDR Enterobacteriaceae, including carbapenem-resistant strains. Further efforts include a program for small molecule LpxC inhibitors targeting Pseudomonas aeruginosa and Acinetobacter baumannii, alongside a therapeutic antibody initiative for gram-negative bacteria.
Achaogen's top competitors include Spero Therapeutics, Melinta Therapeutics and Adaptive Phage Therapeutics.
Achaogen has 10 investors. Key investors include Gates Foundation, Arch Venture Partners, Frazier Healthcare Partners, Alta Partners, and 5AM Ventures.